Replies to post #228386 on Biotech Values

[DewDiligence]

GILD is testing its oral PD-L1 inhibitor, GS-4224 for both solid tumors and HBV.

I presume that the goal is a short-course curative regimen rather than continuous viral suppression, as with nukes.